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Abstract
The interleukin-6 (IL-6) and the chemokine CCL5 are implicated in the development and progression of several forms of
tumours including that of the prostate. The expression of the prostate specific membrane antigen (PSMA) is augmented in
high-grade and metastatic tumors. Observations of the clinical behaviour of prostate tumors suggest that the increased
secretion of IL-6 and CCL5 and the higher expression of PSMA may be correlated. We hypothesized that PSMA could be
endowed with signalling properties and that its stimulation might impact on the regulation of the gene expression of IL-6
and CCL5. We herein demonstrate that the cross-linking of cell surface PSMA with specific antibodies activates the small
GTPases RAS and RAC1 and the MAPKs p38 and ERK1/2 in prostate carcinoma LNCaP cells. As downstream effects of the
PSMA-fostered RAS-RAC1-MAPK pathway activation we observed a strong induction of NF-kB activation associated with an
increased expression of IL-6 and CCL5 genes. Pharmacological blockade with specific inhibitors revealed that both p38 and
ERK1/2 participate in the phenomenon, although a major role exerted by p38 was evident. Finally we demonstrate that IL-6
and CCL5 enhanced the proliferative potential of LNCaP cells synergistically and in a dose-dependent manner and that CCL5
functioned by receptor-mediated activation of the STAT5-Cyclin D1 pro-proliferative pathway. The novel functions
attributable to PSMA which are described in the present report may have profound influence on the survival and
proliferation of prostate tumor cells, accounting for the observation that PSMA overexpression in prostate cancer patients is
related to a worse prognosis.
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Introduction
Prostate cancer is the most commonly diagnosed neoplasia in
man in developed countries. Death from prostate cancer occurs
largely in patients with the aggressive androgen-insensitive
metastatic disease. A number of studies have recently demonstrat-
ed that a prominent role in tumor survival and progression can be
attributed to soluble mediators present in the tumor microenvi-
ronment. Among these, Interleukin-6 (IL-6) has a fundamental
role in the regulation of proliferation, apoptosis, angiogenesis and
differentiation in many cell types and it is also implicated in the
development and progression of several forms of tumours
including that of the prostate [1,2]. In fact, the expression of IL-
6 and its receptor is consistently demonstrated in human prostate
cancer cell lines and in freshly isolated cells from human prostate
carcinoma and benign prostate hyperplasia [3,4]. Clinically, the
levels of IL-6 in serum are significantly elevated in many men with
advanced, hormone-refractory prostate cancer [5,6]. Further, IL-6
activates androgen receptor-mediated gene expression in LNCaP
cells in vitro [7,8], suggesting that IL-6 may play a critical role
during the progression of prostate cancer. In addition, over-
expression of IL-6 in androgen-responsive LNCaP cells promotes
their androgen-independent growth in vitro and in vivo [9].
Recently, the chemochine CCL5 (RANTES) was found to be
expressed by human prostate carcinoma cells and reported to
stimulate their proliferation and invasion [10]. Thus, also CCL5
appears to be directly involved in the behaviour of prostate
carcinoma cells. The gene expression of both IL-6 and CCL5 is
mainly regulated at a transcriptional level, by the cooperative
activity of NF-kB transcription factor with members of at least five
different families of transactivators including AP-1 [1]. Noticeably,
the cooperation between NF-kB and AP-1 appears to be essential
for the constitutive deregulated production of IL-6 observed in the
androgen-independent, aggressive prostate cancer cells [11]. Gene
induction occurs depending on the ability of a variety of cell
surface receptors to activate distinct and/or partially overlapping
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intracellular signalling pathways eventually targeting the phos-
phorylation site(s) of one or more MAP kinases (i.e. p38, ERK1/2,
JUNK) committed in turn to activate IL-6 and/or CCL5 gene
transactivators. Cytokines, growth factors receptors, adhesion
molecules and many other membrane-generated signals all share
the ability to efficiently promote IL-6 or CCL5 gene expression
and consequently also their downstream effects. In addition, under
long-term treatment conditions, IL-6 can activate its own gene
expression and, in prostate cancer, autocrine and paracrine loops
involving IL-6 and one of its multiple activators, the TGF-beta,
have been implicated in the regulation of cell proliferation,
survival, and neuroendocrine differentiation [12].
The expression levels of the prostate specific membrane antigen
(PSMA) have been proposed as a useful indicator of the severity of
the disease in prostate cancer [13–15]. PSMA is a type-II integral
membrane protein, predominantly localized to the epithelial cells
of the prostate gland and endowed with folate-hydrolase and
carboxypeptidase activity [13]. Its low expression in normal
prostate epithelial cells increases several fold in high-grade prostate
cancers, in metastatic and in androgen-insensitive prostate
carcinoma [14]. These features have made it emerging as one of
the most promising biomarkers in the diagnosis and treatment of
prostate cancer [14,16]. The clinical observations suggesting a
possible correlation between high levels of IL-6 production and
PSMA expression in high-grade prostate cancer prompted us to
investigate whether a functional relationship may exist between
the presence of PSMA at the cell surface and the level of gene
expression of IL-6. CCL5 was also investigated because it shares
with IL-6 the mechanism of gene induction and the pro-
proliferative activity. The hypothesis that PSMA belonged to the
ever increasing category of molecules endowed with signalling
properties was also suggested by previous observations showing
that silencing, inhibiting or knocking-down PSMA modulates the
adhesion/de-adhesion processes via activation of focal adhesion
kinase (FAK) in LNCaP cells or via activation of p21-activated
kinase1 (PAK1) in normal endothelial cells (HUVEC) [17,18].
Unlike what previously done by others [18,19], we decided to
stimulate rather than to inhibit or silence PSMA at the surface of
LNCaP cells and to overcome the lack of defined PSMA ligand(s)
by cross-linking the extra-cellular domain of the molecule with
specific antibodies.
Here, by using the androgen-independent LNCaP cell line, we
present for the first time evidence that the antibody-mediated
aggregation of PSMA greatly induce the basal gene expression of
both IL-6 and CCL5 in LNCaP cells. Gene induction occurs due
to an activation cascade involving RAS, RAC1, p38 and ERK1/2
MAPKs, leading to the phosphorylation of the p65 subunit of NF-
kB transcription factor. In addition, we demonstrate that both IL-
6 and CCL5 promote the proliferation of LNCaP tumour cells
reaching their maximal activity synergistically. Moreover, we
present a novel finding related to the ability of CCL5 to induced
proliferation in LNCaP cells thank to the activation of STAT5 and
the consequent increase of expression of cyclin D1, a pathway
controlling cell growth in normal and prostate cancer cells. This
newly discovered functions of PSMA implicate this molecule as an
important regulator of the prostate tumour cell growth.
Materials and Methods
Chemicals, cell culture reagents and antibodies
PD098059 and SB202190 inhibitors were from Calbiochem-
Novabiochem (San Diego, CA). Poly-D-lysine, trypsin and
protease inhibitors were from SIGMA (SIGMA, Milan, Itay),
whereas phenylmethylsulfonyl fluoride, antipain and soybean
trypsin inhibitor were from Roche Diagnostics (Mannheim,
Germany). The Hybond-P PVDF membranes and the ECL plus
Western Blotting Detection System were from Amersham
Bioscience Inc. (Freiburg, Germany). RPMI 1640 medium and
glutamine were from Societa` Prodotti Antibiotici (Milan, Italy).
Fetal bovine serum (FBS) was from Celbio (Pero, Milan,
Italy).(Fab)2 goat anti-mouse Ig and anti-VCAM-1 were from
Immunotech (Marseille, France); FITC-labeled (Fab)2 goat anti-
mouse Ig and anti p65 phosphorylated mAb were from Becton-
Dickinson (San Jose`, CA); the anti PSMA mAb J591, described by
H. Liu et al. [20] was kindly supplied by Dr. N.H. Bander
(Medical College of Cornell University, New York); the 7E11c
mAb, recognizing a cytosolic epitope of PSMA was purified from
the supernatant of the hybridoma HB-10494 (ATCC, American
Type Culture Collection, Rockville Pike, MD); anti-phospho-p38,
anti-p38 polyclonal Abs and anti-phospho-ERK1/2 mAb were
from Cell Signaling Technology (Danvers, MA); anti-STAT 5 and
anti-cyclin D1 polyclonal antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-RAS (clone RAS10) and
anti-RAC (clone 23A8) mAbs were from Upstate Biotechnology
(Lake Placid, NY). The anti-PSMA mAb used for this work was
produced in our laboratory and used in purified form following
affinity chromatography. Briefly, BALB/c mice were immunized
with a soluble recombinant form of PSMA and hybridoma cells
obtained following standard fusion procedures. Hybrids were
screened by flow cytometry using PSMA positive (LNCaP) and
PSMA negative (DU145, PC-3) cell lines.
Cells and cell treatments
The PSMA-positive LNCaP and the PSMA-negative DU145
and PC-3 human prostate carcinoma cell lines were from ATCC.
Cells were maintained in vitro by serially passaging in RPMI-10%
FBS at 37uC in a humidified atmosphere of 5% CO2. In the case
of the LNCaP cell line, plating was performed on poly-D-lysine
coated tissue culture plasticware (10 mg/ml). When required, cells
grown to confluence in 24 well plates were incubated with
saturating doses of the appropriate mAb (5 mg/ml, 30 min at
room temperature), washed and placed at 37uC for different times
with (Fab)2-goat anti-mouse (Gam) (10 mg/ml) to induce the
clustering of PSMA molecules at the cell surface (this procedure
will be henceforth designated ‘‘PSMA cross-linking’’). In some
instances, cells were pre-treated (6 h at 37uC) with ERK1/2 (PD
98059) or p38 (SB 202190) inhibitors, used alone or in
combination, at 25 or 50 mM in complete medium. The inhibitors
were present throughout the duration of the assays. Cell-free
supernatants and cells were separately recovered from each sample
of untreated or treated cells 24 h after the addition of the various
compounds. The volume of each cell-free supernatant was
measured and the supernatant used to determine IL-6 and
CCL5 production. Cells corresponding to each supernatant were
lysed and the amount of proteins assessed by Coomassie protein
assay reagent (Pierce, Celbio, Milano, Italy).
Biochemical methods
Cell extracts were prepared from LNCaP cells cultured
overnight with 2.5% FBS and then starved from serum for 2 h.
Protein amount was measured by Coomassie protein assay
reagent. RAS activity was assessed by employing the RAS
activation assay kit (Upstate Biotechnology). Briefly, untreated
and treated cells were lysed for 30 min on ice in a buffer
containing 25 mM Hepes pH 7.5, NaCl 150 mM, 10% Glicerol,
Na orthovanadate 1 mM, Na pyrophosphate 50 nM, Na fluoride
25 mM, MgCl2 10 mM, 1% NP40, phosphatase and protease
inhibitors. The cell lysates (250 mg) were incubated with 10 ml of
PSMA Induces IL-6, CCL5
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glutathione S-transferase (GST)-Raf-RAS binding domain (BD)
(Upstate Biotechnology) coupled to agarose for 1 h at 4uC. The
beads were washed with the lysis buffer, resuspended in 26 SDS
sample buffer, and separated by SDS-Page. Western Blot was
performed with the anti-RAS mAb and immunoreactive bands
were visualized by using a horseradish peroxidase-conjugated
secondary antibody and the ECL system (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden).
RAC1 activity was assessed by employing the RAC activation
assay kit (Upstate Biotechnology). Briefly, cell lysates prepared as
above (250 mg) were incubated with 10 ml of GST-PAK-1-RAC
BD coupled to agarose for 1 h at 4uC. The beads were washed
with the lysis buffer, resuspended in 26 SDS sample buffer and
separated by SDS-Page. Western blotting was performed with the
anti-RAC antibody (Upstate Biotechnology).
To examine p38 and ERK1/2 phosphorylation, untreated and
treated cells were extracted with the buffer indicated above. Equal
amounts of total proteins were boiled in sample buffer and
separated by SDS-PAGE. Following immunoblotting with anti-
phospho-p38 or anti-p38 polyclonal Ab, anti-phospho-ERK1/2
mAb or anti-ERK1/2 polyclonal Ab, immunoreactive bands were
visualized by using horseradish peroxidase-conjugated secondary
antibody and ECL. Film densitometry was carried out with a laser
densitometer and analyzed using a built-in software (LKB,
Bromma, Sweden).
Intracellular phospho-specific flow cytometry
LNCaP cells were treated with ant-PSMA mAb for 30 min at
room temperature, washed and cross-linked with Gam at 37uC for
0, 15 or 30 min. After this time cells were fixed with Fix buffer
(BD) for 10 min at room temperature to arrest signaling activity.
Cells were then washed and permeabilized with 50% ice-cold
methanol for 30 min on ice. Fixed and permeabilized cells were
washed twice, resuspended in phosphate-buffered saline plus 2%
FBS and stained for 30 min at room temperature with monoclonal
PE-conjugated antibody against phospho-NF-kB (S529) (Becton-
Dickinson). Conjugated isotype-matched, non-reactive monoclo-
nal antibody was used as control. Fluorescence signals were
detected using a FACSCalibur flow cytometer (Becton-Dickinson)
and data elaborated by FlowJo software (Tree Star, Ashland, OR).
IL-6 and CCL5 quantitation
IL-6 and CCL5 concentration in cell-free supernatants was
measured with an ELISA kit used according to the manufacturer’s
instructions (Endogen, Woburn, MA). Optical density (OD) values
were plotted onto a standard curve and expressed as pg/ml.
Having measured the volume of cell-free supernatants of each
sample, IL-6 or CCL5 values could be re-expressed as total IL-6 or
CCL5/sample. Total IL-6 or CCL5 of each sample was then
normalized versus the amount of total protein of cell lysate of the
producing cells and calculated as pg IL-6 or CCL5/ mg of protein
lysate.
Cell proliferation assays
Cell proliferation studies were carried out with LNCaP cells
previously cultured with only 1% FBS for 48 h and then treated
with the indicated doses of recombinant IL-6 or CCL5 (Endogen).
In the case of treatment with anti-PSMA mAb the binding and the
cross-linking of anti-PSMA or 7E11c were performed as previously
described in the ‘‘Cells and cell treatments’’ paragraph of the
present section. In the case of anti-CCR5 treatment, the antibody
at the indicated concentrations was preincubated for 2 h at 37uC
before adding the CCL5. During the last 12 h cells were pulsed
with 1 mCi[methyl-3H] thymidine (3H-TdR) (6.7 Ci/mmol) from
NEN Dupont (Boston, MA). Cells were harvested onto glass-fiber
filters and radioactivity measured in a beta-spectrometer. Results
were expressed as the percentage of incorporation of the untreated
control.
Flow cytometry
Cells were incubated with saturating amounts of the indicated
antibody for 1 h on ice and then washed three times with cold
RPMI medium. The cells were then incubated with 2 ml of a goat
anti-mouse FITC-labeled antiserum (Becton-Dickinson) for 1 h on
ice. After washings cells were analyzed by a Facs Canto instrument
(Becton-Dickinson).
Statistical analysis
Statistical analysis of results was performed applying the
parametric unpaired t test. Significance was accepted when
p,0.05.
Results
Characteristics of the anti-PSMA mAb used for the
present study
Biochemical and functional studies shown in this paper were
performed with an anti PSMA mAb (henceforth designated ‘‘anti-
PSMA mAb’’) produced by our group. Specificity for PSMA is
shown in Fig. 1. Staining, competition and immuneprecipitation
experiments were performed with LNCaP cells and the anti-
PSMA mAb was compared with the J591 mAb, a reference mAb
recognizing an extra-cellular epitope of the PSMA molecule [20].
Flow cytometry of cells stained with anti-PSMA or J591 mAbs
demonstrated that both mAbs recognized a surface molecule
expressed at comparable levels on LNCaP cells (Fig. 1A). No
staining was instead observed with the PSMA negative DU145 or
PC3 cell lines (not shown). Competition experiments, performed
with biotinilated J591 mAb revealed by FITC-streptavidin,
demonstrated that the number of positive cells and the mean
fluorescence observed following J591 staining was progressively
decreased when cells were pre-treated with increasing amounts of
non-conjugated anti-PSMA mAb (Fig. 1, B), thus demonstrating
that our anti-PSMA mAb specifically recognizes an epitope of the
extra-cellular domain of the molecule identical or spatially close to
that identified by the J591 mAb. Immunoprecipitations of crude
cell lysates revealed the ability of our anti-PSMA mAb to
immunoprecipitate a protein of the same apparent molecular
weight (110 kD) of that immunoprecipitated using J591 mAb or
7E11c mAb, this last recognizing an intracellular epitope of PSMA
(Fig. 1C). Collectively, these results demonstrated that our anti-
PSMA mAb specifically recognizes an extra cellular epitope of
PSMA. Results obtained at a single cell level were extended by
immunohistochemistry to human tissues, demonstrating that the
reactivity of anti-PSMA mAb overlapped that of J591 (not shown)
PSMA recruitment with specific antibodies activates the
MAPKs p38 and ERK1/2 and the small GTPases RAC1 and
RAS in LNCaP cells
To test whether PSMA was able to transduce intracellular
signals leading to p38 and/or ERK1/2 phosphorylation, LNCaP
cells were subjected to PSMA cross-linking by anti-PSMA-specific
antibodies as adherent, confluent monolayers. PSMA molecules,
recognized by the anti-PSMA mAb were induced to cluster at the
cell membrane due to the binding of a goat anti-mouse IgG
antiserum (Gam) added to cell cultures at 37uC for the indicated
times. Controls included treatment with anti VCAM-1, with
PSMA Induces IL-6, CCL5
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7E11c or with Gam alone and the use of untreated cells. Cells
were then washed and used as a source of cell lysates. We first
assayed the phosphorylation of p38 and ERK1/2 in crude lysates
obtained from the same cell cultures immunoblotted with
antibodies specifically detecting the active, phosphorylated form
of the two kinases. As shown in Fig. 2A and B, ERK1/2 and p38
were found activated at low levels in untreated LNCaP cells. Upon
PSMA cross-linking, both ERK1/2 and p38 became considerably
Figure 1. Reactivity of anti-PSMAmAb. Panel A: representative flow cytometry of LNCaP cells stained with anti-PSMA or with J591 mAb. Controls
are represented by cells goat anti-mouse-FITC IgG only. Panel B: flow cytometry of LNCaP cells incubated with biotinylated J591 mAb (B-J591) with or
without pretreatment (45 min on ice) with anti-PSMA at the indicated concentrations or with non-biotinylated J591 mAb as control. Antibody
binding was revealed by FITC-Avidin (F-Avidin). The percentage of positive cells and the Mean Fluorescence Intensity observed under the different
conditions are representative of two independent experiments performed with independent cultures. Panel C: Western blot analysis of LNCaP cell
lysates immuneprecipitated with the indicated mAbs, and then probed with the anti-PSMA mAb followed by a goat anti-mouse antiserum labelled
with horseradish peroxidase. The apparent molecular weight of PSMA band is indicated by the arrow.
doi:10.1371/journal.pone.0004608.g001
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phosphorylated at 10 min. Sustained levels of phosphorylation
lasted up to 20 min, and then returned to basal levels. It is known
that the small GTPases RAS and RAC1 lie upstream on the
MAPKs activation pathways [21]. Thus, to examine if PSMA
cross-linking could activate also RAC1 in LNCaP cells, we
performed an activation assay with a GST-Pak fusion protein
which is able to bind and precipitate the active form of RAC1. As
shown in Fig. 2C, PSMA cross-linking determined endogenous
RAC1 activation in the same lysates. Similar results were obtained
in the case of RAS, whose constitutive activation level was greatly
augmented upon PSMA cross-linking (Fig. 2D). Cross-linking
performed with an isotype matched mAb recognizing VCAM-1
failed to induce activation in all assays and at all points of the time-
course (Fig. 2, all panels). Gel densitometry of independent
experiments performed with different cell lysates confirmed the
significance of the increased activation of ERK1/2, p38, RAC1
and RAS observed following PSMA, but not VCAM-1 cross-
linking (Table 1). Because the time-course of RAS and RAC1
activation paralleled that of p38 and ERK1/2, these results overall
indicate that PSMA is able to induce a sustained activation of the
RAS- and RAC-MAPK pathways.
PSMA-elicited phosphorylation of p38 and ERK1/2
induces the activation of NF-kB transcription factor
It is well established that p38 and ERK1/2 have a role in the
process of activation of NF-kB transcription factor, and that NF-
kB plays a major function in the transcriptional control of various
cytokines and chemokines, including IL-6 and CCL5 [1]. To
investigate whether NF-kB activation was induced in LNCaP cells
by the cross-linking of PSMA, cells were treated as described in
Fig. 2 and stained with a mAb recognizing the phosphorylated
Serine 529 (pS529) located in the transactivation domain of the
p65 subunit of the human NF-kB. As the pS529 containing
domain is unmasked only after detachment of NF-kB inhibitors
Figure 2. Kinetics of ERK1/21/2, p38, RAC 1 and RAS phosphorylation induced by PSMA cross-linking. LNCaP cells were left untreated
or subjected to PSMA cross-linking for the indicated times at 37uC. An anti-VCAM-1 mAb was used as the isotype matched control. Panels A and B:
p38 and ERK1/2 activation was assessed in crude lysates. Equal amounts (20 mg) of total proteins were boiled in sample buffer and separated by SDS-
PAGE. Following immunoblotting with an anti-phospho-p38 or anti-phospho-ERK1/2 mAb, immunoreactive bands were visualized by using
horseradish peroxidase-conjugated secondary antibody and the ECL system. Panels C and D: RAC1 and RAS activation was evaluated by a specific
assay as described in the Material and Methods section. Bound active GTP-RAC and GTP-RAS molecules were analyzed by Western blotting using an
anti-RAC1 or anti-Ras mAb and visualized as above. Total amount of ERK1/2, p38, RAC1 and RAS in crude lysates are shown as loading control at the
bottom of each gel. Results are representative of one of three independent experiments.
doi:10.1371/journal.pone.0004608.g002
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induced by stimulation, the exposure of pS529 is considered a
marker of NF-kB nuclear translocation and activation in normal
and neoplastic cells of different origin. Additionally, phosphory-
lated S529 further augments NF-kB transactivation potential [22].
Controls were represented by cells left untreated, treated with an
isotype-matched IgG1 antibody or subjected to VCAM-1 cross-
linking. The results of flow cytometry analysis (Fig. 3) demon-
strated that the mean fluorescence intensity (MFI) of LNCaP cells
(9.260.9 SEM) was greatly augmented following PSMA cross-
linking, peaking at 15 min from stimulation and declining 30 min
later (230%630 SEM and 160%620 SEM of control cells,
respectively), thus implying that NF-kB activation had occurred.
No increase of MFI was instead detected at the various points of
the time course in the presence of the control antibody or VCAM-
1 cross-linking.
PSMA cross-linking enhances the production of IL-6 and
CCL5 in LNCaP cells in a p38 and ERK1/2 dependent
manner
Results shown in Fig. 2 and 3 demonstrated that cross-linking of
PSMA recruited a signalling pathway eventually leading to NF-kB
activation and nuclear translocation. The contribution of PSMA
to the regulation of the production of IL-6 and CCL5 in LNCaP
cells was then investigated in cross-linking experiments carried out
as in Fig. 2. Further, we analyzed the role of PSMA-activated p38
and ERK1/2 in a loss-of-function condition achieved by using two
pharmacological inhibitors: SB 202190 (SB), a compound binding
specifically p38 and blocking reversibly its enzymatic activity or
PD 98059 (PD), an inhibitor specifically preventing the activation
of the ERK1/2-activating kinase MEK-1 [23]. LNCaP cells were
stimulated as confluent monolayer and harvested 24 h later. To
determine the basal and inducible release of IL-6 and CCL5 in
culture, LNCaP cells and the corresponding cell-free supernatants
were separately recovered from each treated or untreated cell
culture. Cell lysates and cell-free supernatants were used to
determine respectively the total protein amount and IL-6 and
CCL5 accumulation in the supernatant of each sample. The
results of IL-6 and CCL5 measurements were then expressed as pg
of IL-6 or CCL5/mg of cell protein lysates. As illustrated in Fig. 4
A, LNCaP cells produced low amounts of IL-6 and of CCL5
basally (11.362 and1463.6 pg/mg total cell protein/24 h,
respectively). The cross-linking of PSMA increased this production
by three-fold in the case of IL-6 and by two-fold in the case of
CCL5 (311%648, p,0.001 and 214%638 p,0.001, respective-
ly), thus demonstrating that PSMA recruitment at the surface of
LNCaP cells powerfully up-regulates the production of both IL-6
and CCL5 at the same time. The cross-linking of the isotype-
Table 1. Kinetics of ERK1/2, p38, RAC1 and RAS activation in LNCaP cells following cross-linking of anti-PSMA, anti-VCAM-1 or
7E11c mAba).
Protein
No
treatment Anti-PSMA cross-linking Anti VCAM-1 cross-linking 7E11c cross-linking
10 min 20 min 40 min 10 min 20 min 40 min 10 min 20 min 40 min
ERK1/2 2366.6b) 4864.4 (p,0.05)c) 3061.2 (p,0.05) 9.263.9 (ns)d) 8.463 (ns) 1162.9 (ns) 9.362 (ns) 8.663.1 (ns) 9.864.7 (ns) 7.461.3 (ns)
P38 2.660.16 30.161.2 (p,0.001) 11.660.9 (p,0.001) 4.260.9 (ns) 5.462.2 (ns) 3.760.2 (ns) 360.7 (ns) 4.862.8 (ns) 3.263.4 (ns) 4.562.1 (ns)
RAC1 17.262.1 27.662.2 (p,0.05) 40.363.9 (p,0.01) 1162.9 (ns) 2968.8 (ns) 2764.2 (ns) 19.263.8 (ns) nde) nd nd
RAS 6.462.5 23.562.8 (p,0.001) 23.161.9 (p,0.001) 4.863.8 (ns) 13.263.6 (ns) 8.465 (ns) 20.569 (p,0.01) nd nd nd
a)The 7E11c mAb recognizes an intracellular PSMA epitope and is therefore used as a further control of the experiment described.
b)Results of gel densitometry are expressed as the ratio6SEM of activated/total protein as evaluated by measuring the respective areas.
c)Statistical significance is reported with respect to the ‘‘No treatment’’ data.
d)ns = not significant.
e)nd =not determined.
doi:10.1371/journal.pone.0004608.t001
Figure 3. NF-kB activation induced by PSMA crosslinking.
LNCaP cells were subjected to stimulation by cross-linking of PSMA or
of VCAM-1 for 45 min at room temperature and then cultured for the
indicated times at 37uC. The cells were then harvested, washed,
permeabilized and stained with a PE-labelled anti-phosphorylated NF-
kB p65 antibody. Cells were then analyzed by flow cytometry. The MFI
was recorded. An isotype-matched IgG1 antibody was used to mock-
treat LNCaP cells; the Figure illustrates a representative experiment out
of three performed independently. MFI values of controls were:
untreated cells 9.2260.9, cells treated with an anti-VCAM-1 mAb
5.74+0.09, cells treated with a mouse IgG1 mAb 5.0260.3. No
substantial differences in the control samples were observed at the
various time points of the experiments. MFI of Anti-PSMA cross-linked
cells were: 22.0362.2 and 15.661.3 at 15 min and 30 min, respectively.
p values of samples treated with anti-PSMA mAb were ,0.01 at 15 min
and 30 min, respectively, with respect to the untreated cells. The first
panel from top (mouse IgG1) is the plot corresponding to time 0.
doi:10.1371/journal.pone.0004608.g003
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matched anti VCAM-1 mAb lacked instead any significant activity
(155%652 and 133%611, respectively).
As also illustrated in Fig. 4 A, the p38 inhibitor SB used at
50 mM concentration almost abrogated both the basal and the
PSMA-induced IL-6 production (70%62.5 p,0.01 and
87.4%620 p,0.05, respectively), whereas at 25 mM the decrease
observed did not reach significance. The ERK1/2 inhibitor PD
showed a poorer activity than SB, as it diminished the IL-6
produced basally, (30%65 p,0.05 and 50%67 p,0.05, at
25 mM and 50 mM, respectively) but failed to show any effect on
that induced by PSMA cross-linking. Accordingly, IL-6 reduction
observed in the presence of both inhibitors (both used at 25 mM
concentration) overlapped that dependent on the sole SB. Similar
results were obtained regarding the production of CCL5. As
shown in Fig. 4 B, the basal production of CCL5 diminished in a
dose-dependent manner in the presence of SB, reaching
significance at 50 mM (45%612, p,0.01). The PSMA-induced
production of CCL5 was significantly reduced already at 25 mM
Figure 4. Inducing activity of PSMA cross-linking on IL-6 and CCL5 expression and role of PSMA-activated p38 and ERK1/2 . IL-6
(panel A) and CCL5 (panel B): production by LNCaP cells left untreated (open bars), stimulated by cross-linking via anti PSMA mAb (filled bars) or anti-
VCAM-1 mAb (dashed bars) in the presence or in the absence of single or combined inhibitors (SB and PD) at the indicated doses (SB50 = 50 mg/ml,
SB25= 25 mg/ml; PD50= 50 mg/ml, PD25= 25 mg/ml; SB/PD25= combinations of SB+PD at 25 mg/ml each). Control and treated cell cultures were
washed, cultured for further 24 h before collecting cells and cell-free supernatants. IL-6 and CCL5 accumulation in each supernatant was measured by
ELISA and expressed as pg/mg of cell lysates/24 h. Inhibitors were added to the cells 6 h prior to stimulation and maintained throughout the
duration of the experiment. Values represent the mean6SEM of results of four experiments performed in duplicates. Stars on top of the bars indicate
statistical significance as follows: p,0.001, ***; p,0.01, **; p,0.05, *.
doi:10.1371/journal.pone.0004608.g004
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SB and flattened out to basal levels at 50 mM (38%64,p,0.01
and 72%616, p,0.01, respectively). Also in the case of CCL5 the
ERK1/2 inhibitor PD performed less efficiently. The basal
production of CCL5 was not significantly affected by the presence
of PD and the PSMA-induced CCL5 production was only halved
although the effect was significant (p,0.001), with no dose-
dependency (49%64, p,0.001 PD used at 50 mM; 42612,
p,0.01, PD used at 25 mM). No greater activity was obtained by
using a mixture of the two inhibitors used at 25 mM concentration.
The possibility that the mix of inhibitors used at higher
concentrations may be effective could not be explored because
the compounds precipitate when the concentration is brought
close to 100 mM. The effect of SB and PD on IL-6 and CCL5
produced by cells stimulated by the cross-linking of the control
mAb were similar to those of untreated cells (Fig. 4 A and B).
Collectively, the results shown in Fig. 4 demonstrate that the
activation of p38 and ERK1/2 elicited by PSMA cross-linking
regulates the expression of IL-6 and CCL5 genes in LNCaP cells
like in other pathological and normal epithelial cells [24,25].
Moreover, as also observed in other instances our results underline
the fact that p38 exerts a wider and greater activity than ERK1/2
on IL-6 and CCL5 gene expression [24,25].
Proliferation of LNCaP cells is inducible by IL- 6, CCL5 or
by cross-linking of PSMA
Proliferation assays were then carried out to evaluate whether
the increased availability of IL-6 and CCL5 in a neoplastic
microenvironment would affect the growth of the LNCaP tumour
cell line.
As illustrated in Fig. 5 A, the rate of unlimited proliferation of
LNCaP cells was increased by the addition of recombinant IL-6 or
CCL5 in a dose-dependent manner. IL-6 exerted the maximal
activity at 100 ng/ml (175616, p,0.01) whereas CCL5 promoted
a similar enhancement already at 5 ng/ml (146%62 of increase,
p,0.05), although only a subset (8–10%) of strongly positive
CCR5 cells could be detected in our LNCaP cells population
when FBS was lowered in culture to 1% (S. Grasso, personal
observation). IL-6 and CCL5 appeared to act synergistically in
inducing LNCaP cells proliferation, as demonstrated by the
finding that the addition of as little as 1 ng/ml of IL-6 to the most
effective dose of CCL5 raised the LNCaP cells proliferation up to
values which were significantly higher than those of controls
(168%62.9, p,0.001), and, perhaps more importantly, greater
than those observed in the presence of 5 ng/ml of CCL5 (p,001).
As shown in Fig. 5 B the induction of proliferation induced by
CCL5 was almost abrogated by blocking CCR5 with specific
antibodies. No interference was instead observed in the presence
of 7E11c antibody, used as isotype-matched control, thus putting
into evidence a direct correlation between the burst of LNCaP
cells proliferation and the CCL5 interaction with its receptor
CCR5. It has been reported that the triggering of CCR5 by CCL5
is rapidly followed by JAK-STAT phosphorylation, more
specifically by STAT1 and/or STAT3 and/or STAT5, depending
on the cellular system [26–28]. It has been also reported that
STAT5 phosphorylation regulates the expression of cyclin D1 in
tumor cells including those of prostate [29,30]. To investigate the
downstream effects of CCR5 engagement in LNCaP cells, the cells
were cultured in the presence of 5 ng/ml of CCL5 for the
indicated times and then analysed as for the expression of STAT 5
and Cyclin D1 by immunoblotting with specific antibodies. As
illustrated in Fig. 5 C phosphorylated STAT5 appeared as a
doublet at 30 min. The doublet lowered its intensity at 1 h to
return to the almost undetectable level observed in untreated cell
at 3 h. Consistently, the amount of cyclin D1 was found more than
doubled at 1 h and at 3 h, thus indicating that CCL5 can regulate
LNCaP cells proliferation in a STAT 5-Cyclin D1 dependent way.
Taken toghether, these results demonstrate that the antibody-
mediated clustering of PSMA at the LNCaP cells surface activates
signalling pathways able to directly or indirectly control the
LNCaP cells growth. To confirm that the complex series of
phenomena reported in the previous paragraphs led to LNCaP
cells proliferation we decided to test if the cross-linking of PSMA
would indeed induce the LNCaP cells proliferation. As shown in
Fig. 5D LNCaP cells proliferation was found to be increased
following PSMA cross-linking (175%611, p,0.05), whereas the
bindings of the sole anti-PSMA, of 7E11c or the cross-linking of
7E11c were all devoid of significant activity.
Discussion
In this paper we show for the first time that the tumor
biomarker PSMA, a multi-functional cell surface ectopeptidase
[13], is endowed with an efficient signaling activity in prostate
cancer cells. PSMA recruitment at the surface of LNCaP cells
elicits a signaling wave involving small GTPases RAS, RAC1, and
MAPK p38 and ERK1/2 activation. Consistent with the p38 and
ERK1/2 phosphorylation, the NF-kB transcription factor was also
activated [1] following PSMA stimulation and the minimal basal
level of both IL-6 and CCL5 production was increased two-three
fold. The discrete role of PSMA-mediated activation of p38 and
ERK1/2 was examined under loss-of-function conditions secured
by the blocking activity of kinase-specific chemical inhibitors, used
at concentrations not affecting the adhesion of LNCaP cells nor
the expression of PSMA at their surface (not shown). In this
setting, p38 kinase exerted a wider and greater activity than
ERK1/2 on both the basal and the PSMA-induced expression of
IL-6 and CCL5. A possible explanation of the greater function of
p38 may reside in the different roles played by p38 and ERK1/2
in the activation of NF-kB and NF-IL6, major transactivators of
both IL-6 and CCL5 promoters [1]. We have previously reported
that in normal human thymic epithelial cells p38 MAPK induced
the post-transcriptional activation of both NF-kB and NF-IL6,
whereas ERK1/2 was involved in the activation of NF-kB only.
Consistent with the dual activity of p38, its inhibition with
SB202190 almost abrogated the cytokine production, whereas
ERK1/2 inhibition with PD98059 resulted in a lesser effect
[24,25]. The distinct functions of the two MAPKs may well be
reproduced also in prostate cancer cells, as evidenced by our
results with the inhibitors PD98059 and SB202190, thus
suggesting that also in LNCaP cells p38 MAPK exerts a wider
role than ERK1/2 on IL-6 and CCL5 transcription factors.
The membrane proximal events leading to RAS and RAC1
activation following PSMA recruitment have not been studied yet
and full elucidation of these aspects will require further
investigations.
Irrespective of the composition of the signaling platform used by
PSMA in transducing external stimuli, our results provide
evidence that PMSA can regulate the gene expression of IL-6
and CCL5 in the same LNCaP cells. These results were obtained
following direct stimulation of the molecule under ‘‘in vitro’’
conditions closely resembling a physiological setting and without
substantial cell manipulations. In addition, because biochemical
studies and functional assays were performed with cell lysates and
cell supernatants obtained from the same cell cultures, these results
directly demonstrated that PSMA-elicited signals flowed efficiently
from the membrane to the nucleus. The amount of IL-6 and
CCL5 released in culture by the LNCaP cell line may appear
lower than that produced by other cell lines. However, it has to be
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considered that a low concentration measured in cell supernatants
can be dramatically high for a portion of the cell membrane and
that the LNCaP cell line used by us represents only one of the
multiple clones composing the prostate cancer cell population,
thus emphasizing the importance that the synergic activity of IL-6
and CCL5 on LNCaP cells proliferation described by us may have
in an ‘‘vivo’’ microenvironment. IL-6 has yielded conflicting
results in prostate tumor cell lines including LNCaP. Cell
proliferation, anti-apoptotic activity as well as growth arrest and
neuroendocrine differentiation were all observed following treat-
ment with IL-6 ‘‘in vitro’’ [12]. By contrast, the notion that the
level of IL-6 and its receptor increase during prostate carcinogen-
esis ‘‘in vivo’’ is still unchallenged, so that IL-6 is nowadays
considered a good candidate for targeted therapy in prostate
cancer [12]. Differences in the cellular and experimental systems
employed together with the complexity of the signaling pathway
elicited by cytokines may possibly explain the divergence between
the clinical and the ‘‘in vitro’’ experimental evidence.
Figure 5. Effects of pro-proliferative stimuli on LNCaP cells. A) LNCaP proliferation induced by treatment with CCL5 and/or IL-6. 3H-TdR
uptake of cells after 24 h of culture with CCL5 (grey bars), 72 h of culture with IL-6 (hatched bars) or 24 h of culture with combinations of CCL5 and
IL-6 (crossed bars) at the indicated concentrations. B) 3H-TdR uptake of cells after 24 h culture with 5 ng/ml of CCL5 in the presence or in the absence
of anti-CCR5 or 7E11c antibodies at the indicated concentrations; C) Western blot analysis of cell extracts (20 mg/lane) of LNCaP cells treated with
CCL5 (5 ng/ml) and probed with anti-STAT 5 or with anti-cyclin D1 antibodies. Equal protein loading in all the lanes is confirmed by not specific bands
shown in the middle gel. Arrows indicate phosphorylated STAT5 proteins. Western blotting results are representative of two independent
experiments. D) 3H-TdR uptake of cells 72 h after binding or cross-linking of 7E11c or anti-PSMA antibodies. Values represent the mean6SEM of three
independent experiments performed in triplicates. Stars on the bars indicate statistical significance as in Fig. 4.
doi:10.1371/journal.pone.0004608.g005
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Little is known about CCL5-CCR5 interaction in LNCaP cells,
apart from the pro-proliferative activity previously reported by G.
Vaday et al. [10] and confirmed also in the present paper. The
novel finding presented herein is the ability of CCL5 to activate
STAT 5 thereby regulating the expression of cyclin D1 and
ultimately controlling the LNCaP cell cycle progression.
Overall, it appears that PSMA signaling may be involved at
multiple stages of the LNCaP cell deregulation and possibly also of
in vivo tumorigenesis, because 1) increased ERK1/2 activation
correlates with increasing Gleason score and advanced tumor
stage [31], and 2) increased activation of STAT 5 has been
observed ‘‘in vivo’’ in 65% of human prostate cancers, being
associated with high histological grade and being a predictor of
early disease recurrence [29,30,32]. Moreover, STAT 5 inhibition
induces cell death in human prostate cancer cells [33].
It could be hypothesized that following stimulation via PSMA
the prostate tumor cells augment IL-6 and CCL5 production
which are in turn used as growth factors in both autocrine and
paracrine manner, triggering a cell proliferation/survival loop
conferring resistance to apoptosis and an overall definite
advantage to tumor cell populations. Within this context, the
ability of PSMA to activate RAC1 may be highly relevant,
inasmuch as RAC1 activation decreases the expression of E-
cadherins thereby loosening intercellular adhesions and facilitating
the cytoskeletal rearrangements required for mitosis [34]. If so,
activated RAC1 could therefore favor the response of LNCaP cells
to the mitogenic activity of IL-6 and CCL5 meanwhile
participating to the induction of their expression.
These events may have a direct bearing also on tumor cell
proliferation and survival ‘‘in vivo’’. The prostate gland is
composed mainly of stromal, epithelial, and neuroendocrine cells.
The dynamic balance of cell proliferation, differentiation, and
apoptosis maintains the cellular and tissue homeostasis. This
balance is generated by a continuous cross-talk among these cell
populations resulting from cell-cell contacts and the release of
growth factors, chemokines and neuropeptides acting in a
paracrine and autocrine manner [13]. Deregulation in this
communication circuit may contribute to the derangement of
one or more tissue component(s) of the prostate gland, possibly
resulting in benign prostate hyperplasia or prostate carcinoma.
The pathway components here described are already the targets of
therapeutic interventions with pharmacologic or biotechnologic
inhibitors in other types of epithelial tumors [21]. Therefore, also
in prostate tumors the biochemical intermediates involved in NF-
kB activation and augmented IL-6/CCL5 gene expression might
represent adequate therapeutic targets aiming at interfering with
one or more of the MAPKs activation pathway(s), thereby
counteracting their effects on tumor cell proliferation and
migration
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